TransMedics Group, Inc.

BST:8T8 Stock Report

Market Cap: €2.0b

TransMedics Group Management

Management criteria checks 3/4

TransMedics Group's CEO is Waleed Hassanein, appointed in Aug 1998, has a tenure of 26.33 years. total yearly compensation is $6.76M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 1.4% of the company’s shares, worth €27.75M. The average tenure of the management team and the board of directors is 3.7 years and 11.4 years respectively.

Key information

Waleed Hassanein

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage9.4%
CEO tenure26.3yrs
CEO ownership1.4%
Management average tenure3.7yrs
Board average tenure11.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Waleed Hassanein's remuneration changed compared to TransMedics Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$33m

Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$7mUS$634k

-US$25m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$575k

-US$36m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$48m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$7mUS$535k

-US$44m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$2mUS$534k

-US$29m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$36m

Dec 28 2019US$3mUS$449k

-US$34m

Sep 28 2019n/an/a

-US$32m

Jun 29 2019n/an/a

-US$29m

Mar 30 2019n/an/a

-US$26m

Dec 29 2018US$524kUS$384k

-US$24m

Sep 29 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$20m

Dec 30 2017US$601kUS$351k

-US$21m

Compensation vs Market: Waleed's total compensation ($USD6.76M) is above average for companies of similar size in the German market ($USD1.58M).

Compensation vs Earnings: Waleed's compensation has been consistent with company performance over the past year.

CEO

Waleed Hassanein (56 yo)

26.3yrs

Tenure

US$6,758,070

Compensation

Dr. Waleed H. Hassanein, M.D. is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He Founded TransMedics, Inc. in August 1998 and h...

Leadership Team

NamePositionTenureCompensationOwnership
Waleed Hassanein
Founder26.3yrsUS$6.76m1.4%
€ 27.8m
Nicholas Corcoran
Senior Vice President of Supply Chain & Operations1.9yrsUS$2.52m0.0096%
€ 190.5k
Anil Ranganath
Senior VP1.4yrsUS$2.35m0.026%
€ 525.9k
Tamer Khayal
Chief Commercial Officer18.9yrsUS$2.63m0.062%
€ 1.2m
Gerardo Hernandez
Chief Financial Officerno datano datano data
Miriam Provost
Vice President of Global Regulatory Affairs5.5yrsUS$813.47kno data

3.7yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 8T8's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Waleed Hassanein
Founder26.3yrsUS$6.76m1.4%
€ 27.8m
Edwin Kania
Independent Director21.9yrsUS$220.28k0.91%
€ 18.0m
Merilee Raines
Independent Director3.9yrsUS$238.62k0.0036%
€ 70.5k
James Tobin
Independent Chairman13.9yrsUS$262.32k0.52%
€ 10.3m
Edward Zavala
Member of Advisory Boardno datano datano data
Gayle Winters
Member of Advisory Boardno datano datano data
Ryszard Smolenski
Member of Advisory Boardno datano datano data
Bruce Rosengard
Member of Advisory Boardno datano datano data
Scott D. Solomon
Member of Advisory Boardno datano datano data
Robert Kormos
Member of Advisory Boardno datano datano data
Edward Basile
Independent Director8.8yrsUS$232.26k0.0022%
€ 43.3k
Thomas Gunderson
Independent Director8.3yrsUS$237.74k0.0036%
€ 70.5k

11.4yrs

Average Tenure

70.5yo

Average Age

Experienced Board: 8T8's board of directors are seasoned and experienced ( 11.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TransMedics Group, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
William PlovanicCanaccord Genuity
Kristen StewartCL King & Associates, Inc.